On Nov. 9, a federal grand jury in Maryland handed up an indictment charging Lauren Stevens, a retired GlaxoSmithKline (GSK) attorney and vice president, with obstruction, concealment and false statements. The charges arose out of Stevens’ representation of GSK in connection with a Food and Drug Administration investigation into the company’s marketing and promotion of the prescription drug Wellbutrin. Without question the indictment, which includes one count of obstruction of an official proceeding, one count of falsification/concealment of documents, and four counts of false statements, has sent shockwaves through the ranks of in-house and outside counsel alike.
Stevens’ counsel has issued a public statement proclaiming her innocence and her resolve to take the matter to trial if need be to obtain vindication. In the same statement, counsel also stated that Stevens’ actions were fully consistent with “the advice provided her by a nationally prominent law firm retained by her employer specifically because of its experience in working with FDA.”
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
